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Abstract
Mutations in mitochondrial aminoacyl-tRNA synthetases are an increasingly recognized cause of 
human diseases, often arising in individuals with compound heterozygous mutations and 
presenting with system-specific phenotypes, frequently neurologic. FARS2 encodes mitochondrial 
phenylalanyl transfer RNA synthetase (mtPheRS), perturbations of which have been reported in 6 
cases of an infantile, lethal disease with refractory epilepsy and progressive myoclonus.
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Here we report the case of juvenile onset refractory epilepsy and progressive myoclonus with 
compound heterozygous FARS2 mutations. We describe the clinical course over 6 years of care at 
our institution and diagnostic studies including electroencephalogram (EEG), brain magnetic 
resonance imaging (MRI), serum and cerebrospinal fluid analyses, skeletal muscle biopsy 
histology, and autopsy gross and histologic findings which include features shared with Alpers-
Huttenlocher syndrome, Leigh syndrome, and a previously published case of FARS2 mutation 
associated infantile onset disease. We additionally present structure-guided analysis of the relevant 
mutations based on published mitochondrial phenylalanyl transfer RNA synthetase and related 
protein crystal structures as well as biochemical analysis of the corresponding recombinant mutant 
proteins.
Keywords
FARS2; progressive myoclonus epilepsy; mitochondrial tRNA synthetase
Introduction
Defects in nuclear genes encoding mitochondrial aminoacyl-tRNA synthetases (mt-aaRS) 
are increasingly linked to a variety of pediatric and adult onset disorders1, many with 
relative selectivity of organ systems affected, particularly the central nervous 
system2, 3, 4, 5, 6. The mechanism by which perturbations of aminoacyl-tRNA synthetases 
produce clinical phenotypes remains unclear, but is generally thought to involve a defect in 
mitochondrial translation, defects in other effects of which have been linked to other human 
diseases with similar phenotypes7.
FARS2 (encoding mitochondrial phenylalanyl transfer RNA synthetase) is the nuclear 
encoded aminoacyl-tRNA synthetase required for the charging of the cognate mitochondrial 
tRNA with phenylalanine. Defects in this enzyme would presumably impact the expression 
of the 13 mitochondrially encoded peptides, including subunits of the mitochondrial 
respiratory chain8. To date, six individuals with FARS2 mutations (3 siblings with 
homozygous missense mutations11, 2 siblings with compound heterozygous missense 
mutations10, and 1 infant with a missense mutation and a large deletion9) have been 
reported, all presenting with a clinical phenotype of infantile onset refractory epilepsy and 
myoclonus (Table 1)9, 10, 11. In all cases there was a characteristic, relative specificity of the 
phenotype to the central nervous system (CNS), all but one were deceased by age 3 – 24 
months at the time of reporting. Of the 3 with MRI findings reported, all had abnormalities 
ranging from isolated white matter abnormalities9 to cortical atrophy with putaminal signal 
abnormalities10, and subdural fluid collections11. Decreased COX staining was reported in 
two patients10, 11, but no ragged red fibers were observed in either of two patients with 
reported muscle biopsy9, 10. Serum lactate elevations were reported in three cases9, 10. In the 
sole individual for whom autopsy information was available, an Alpers-Huttenlocher-like 
features were reported including brain weight <30% of normal, generalized atrophy, gliosis, 
and subtotal laminar necrosis of the entire cortical ribbon10. The missense mutations 
reported in compound heterozygote and homozygote patients were all highly conserved in 
eukaryotic but not prokaryotic PheRS. One missense mutation from compound heterozygote 
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patients is located at the ATP-binding site while the other lies at an interdomain interface. 
The missense mutation of the homozygous patients maps to a distinct interdomain 
interface10. Recombinant mutant proteins for each of the missense mutations demonstrated 
decreased or mildly decreased catalytic efficiency and more severely impacted refolding 
compared to wild type in vitro10.
Here, we report a case of a young woman with novel compound heterozygous FARS2 
mutations and a CNS-specific phenotype of childhood onset refractory epilepsy, progressive 
myoclonus with features in some brain regions reminiscent of Alpers-Huttenlocher 
syndrome and a previously published case of FARS2 mutation associated infantile onset 
disease10 as well as a region with findings similar to Leigh syndrome in addition to 
characterization of enzyme kinetics and apparent binding affinities of recombinant, mutant 
mtPheRs proteins.
Materials and Methods
Bioinformatics and structure-guided analysis
Multiple sequence alignments were performed using CLC Sequence Viewer Version 6.8.2 
(CLC Bio, Qiagen). Crystal structures were reviewed and graphics created using Pymol12.
Functional assays
Protein Expression and Purification—E. coli Rosetta (DE3) cells containing pRARE 
plasmids encoding tRNAs for rare codons were transformed with either WT plasmid 
pET21c-PheRS (a gift from L. Spremulli, University of North Carolina, Chapel Hill, NC, 
USA) or mutant mtPheRS plasmids P85A and H135D. Point mutations were introduced by 
site directed mutagenesis using the QuickChange protocol (Stratagene). Cultures were 
grown at 37°C to OD = 0.8 and induced with 0.5 mM IPTG for 4 h. Cells were harvested, 
sonicated and supernatant was collected after centrifugation at 25 000×g for 1 h. The 
supernatant was applied to a TALON metal affinity resin column (Clontech), followed by 
washing and the protein was eluted with 25 mM Tris–HCl, pH 8.0, 300 mM NaCl, 250 mM 
imidazole and 10% glycerol. Fractions containing mtPheRS were checked for 
electrophoretic purity by SDS–PAGE, pooled and dialyzed overnight at 4°C in 50 mM Tris–
HCl, pH 7.5, 5 mM MgCl2 and 100 mM KCl. The purified enzyme was concentrated, 
adjusted to 50% (v/v) glycerol and aliquots were stored at -80°C. E. coli tRNAPhe was made 
by T7 runoff transcription as previously described13; 10. DNA template for tRNA 
transcription was generated from plasmids carrying tRNA genes by PCR amplification. The 
tRNA was phenol chloroform extracted and purified on a DEAE sepharose column, as 
described previously13, 10.
In vitro tRNA Aminoacylation—Endpoint in vitro aminoacylation was performed at 
37 °C in aminoacylation buffer [100mMNa-Hepes (pH 7.2), 30mMKCl, 2mM ATP, and 10 
mM MgCl2] containing 40 μM L-[14C]Phe (174 cpm pmol–1; Perkin-Elmer Lifesciences), 5 
μM E. coli tRNAPhe transcript, and 100 nM mtPheRS. 8 μl aliquots were removed and 
spotted on 3MM filter disks (Whatman), washed three times in 10% trichloroacetic acid, 
once with 95% ethanol, and then dried. The amount of radioactivity retained was determined 
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by liquid scintillation counting. Steady state kinetics for tRNAPhe were determined at 37 °C 
as described previously with concentrations of in vitro transcribed E. coli tRNAPhe varying 
between 0.1 and 5 μM and enzyme added to a final concentration of 100 nM13.
ATP-PPi Exchange—ATP-PPi exchange rate for amino acid activation was determined 
according to standard methods as previously described13. Reactions were carried out at 
37 °C in a medium containing 100 mM Na-Hepes (pH 7.2), 30 mM KCl, 10 mM MgCl2, 2 
mM NaF, 2 mM ATP, 2 mM [32P]PPi (2 cpm/pmol), Phe (15 μM), and 50 nM mtPheRS. 
After 1–5 min, 25 μl of the reaction were removed and added to a solution containing 1% 
charcoal, 5.6% HClO4, and 75 mM PPi. The charcoal-bound ATP was filtered through a 3 
MM Whatman filter discs under vacuum and washed three times with 5 ml of water and 
once with 5 ml of ethanol. The filters were dried, and the radioactivity content was 
determined by liquid scintillation counting.
Thermostability Assa—To assay protein stability, active fractions of 5 μM of all the 
protein samples were incubated at 37 °C. Enzyme activity was monitored by active-site 
titration and was performed in 50-μL reaction mixtures containing 100 mM Na-Hepes (pH 
7.2), 30 mM KCl, 10 mM MgCl2, 2 mM ATP, 40 μM L-[14C]Phe (174 cpm pmol–1). 
Pyrophosphatase was also added to ensure a unidirectional formation of aminoacyl 
adenylate. The reaction was initiated by the addition of mtPheRS to a reaction mixture 
preincubated at 37 °C for 5 min. After addition of the enzyme, the reaction was performed 
for 10 min at 37 °C and then filtered through a nitrocellulose membrane (PROTRAN BA85; 
Whatman) prewashed with cold 0.5× aminoacylation buffer. The filters were then washed 
with 3 mL of cold 0.5× aminoacylation buffer and dried at 80 °C for 15 min. The amount of 
radioactivity retained was quantified by liquid scintillation counting.
Patient studies
Transient elevations of serum lactate were noted as high as 6.4mmol/L (normal range 0.5-2.2 
mmol/L). Muscle biopsy included examination of skeletal muscle of the right thigh using 
hematoxylin and eosin stain, modified Gomori's trichrome, NADH reductase, oil red O, 
PAS, COX/SDH and ATPase (at pH 4.3, 4.6, and 9.4) stains as well as electron microscopy 
by standard methods. Microscopic analysis of formalin-fixed brain tissue was performed 
using hematoxylin, eosin, and luxol blue stains per standard methods.
Spectrophotometeric analysis of oxidative phosphorylation, skin fibroblast pyruvate 
dehydrogenase and pyruvate carboxylase activity, and butyrobetaine levels were performed 
at the Center for Inherited Disorders of Energy Metabolism (CIDEM, Case Western Reserve 
University). Assessment of mitochondrial DNA content of skeletal muscle was performed by 
qPCR analysis at Baylor University.
Results
Genetic findings
Dual genome panel by massively parallel sequencing (Baylor College of Medicine – 
MitomeNGS) revealed three nuclear variants of unknown significance and two 
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mitochondrial variants of unknown significance. Nuclear variants included two mutations in 
FARS2: c.253C>G (p.P85A, exon 2) and c.403C>G (p.H135D, exon2) as well as a single 
missense mutation in the pyruvate carboxylase gene PC, c.2786C>G (p.A929G, exon 20). 
The PC variant was predicted to be benign due to only moderate evolutionary conservation 
of Alanine-929 and inconsistency with the above reported clinical phenotype. A whole 
exome sequencing study was also performed (GeneDx, Gaithersburg, MD) that confirmed 
the two variants in the FARS2 gene, and demonstrated compound heterozygosity, with one 
allele inherited from each parent. No other significant findings were found by whole exome 
sequencing.
Bioinformatics and structure-guided analysis
To better understand potential biologic implications of the FARS2 mutations identified, 
bioinformatics and crystal structure-guided analysis were undertaken. Multiple sequence 
alignments of orthologous enzymes from mouse, chicken, amphibian, insect, yeast, and 
bacterial species were performed and reveal that the residues affected by the missense 
mutations are highly conserved through evolution, including in Escherichia coli (figure 1). 
Notably, the mutations identified each convert the amino acid in question to a residue with 
distinct biochemical properties. Proline-85, the residue with the most restrictive main chain 
conformations, is mutated to an alanine with both a greater number of potential main chain 
conformations and a more positive hydropathy score14. Likewise, histidine-135 is mutated to 
an aspartate, producing a complete charge reversal of the side chain. Review of the 
published crystal structure of the mtPheRS-Phe-AMP complex15 identifies proline-85 as a 
buried residue while the side chain of histidine-135 is exposed. Both residues lie within the 
larger “catalytic domain,” though neither contacts the Phe-AMP moiety within the active site 
(figure 2a, 4b). Proline-85 constitutes the N-terminal most residue of the “Motif 1” alpha 
helix that, interestingly, is required for oligomerization of class II aminoacyl-tRNA 
synthetases and is speculated to perform other functions as well, though its significance in 
mtPheRs, which functions as a monomer is unclear. Histidine-135 forms part of an alpha 
helix within the region connecting Motif 1 and Motif 2, the second of three highly conserved 
structural elements common to class II aaRSs. In the crystal structure of the orthologous 
protein T. thermophilus-PheRS-bound to tRNAPhe, this conserved inter-motif region forms 
one of two catalytic domain loops that associate with the acceptor stem of the tRNA 
molecule16 (figure 2c). Of note, the T. thermophilus enzyme is a class II enzyme that like 
class I enzymes charges the 2′OH group (as opposed to the 3′-OH group) of the terminal 
tRNA ribose and is composed of two alpha-beta subunit heterodimers, in contrast to human 
mtPheRs which is monomeric but shares significant sequence homology with the alpha 
subunit of T. thermophilus PheRS.
Functional assays
To assess the impact of the identified P85A and H135D substitutions on enzyme function, 
we expressed and purified recombinant mutant mtPheRS proteins in E. coli per established 
protocols13. End point aminoacylation reactions indicated that P85A mtPheRS charges 
tRNA very similarly to WT, but H135D demonstrated severe aminoacylation deficiency 
(figure 3). Determination of the steady-state kinetics for tRNA revealed that mutant P85A 
has a two-fold increase in catalytic efficiency when compared to WT, while kinetic 
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parameters for H135D were unable to be determined using standard techniques, reinforcing 
the previously observed aminoacylation deficiency (figure 3). To better understand the cause 
of this aminoacylation deficiency, we performed end-point pyrophosphate exchange 
experiments. At a phenylalanine concentration of 15 μM, twice the reported KM for human 
mtPheRS, mutant P85A is unable to produce a measurable amount of activity, suggesting 
that the Km of P85A for Phenylalanine is higher than the reported WT value. H135D 
mtPheRS showed a moderate amount of activity, suggesting that the observed 
aminoacylation deficiency is likely due to a defect in tRNA binding and not amino acid 
activation (figure 3).
The stability of WT and mutant proteins was assessed by active site titration after incubation 
at either room temperature or 37 °C. At room temperature, neither mutation has a 
measurable impact on protein stability. However, when tested at 37 °C, mutant P85A 
appears to have decreased stability when compared to WT (figure 3a, 3b).
Clinical Phenotype
The patient was the second child of healthy, non-consanguineous parents born without 
complication at 38 weeks gestation via normal spontaneous vaginal delivery. The pregnancy 
was complicated by gestational diabetes; the perinatal period was unremarkable. She was 
noted to have no major dysmorphic features. As an infant she was noted to have both motor 
and speech delays, first walking independently at 17 months, running at 24 months, and 
requiring a gait belt for safe ambulation at 5 years of age. Fine motor delays were likewise 
noted through school age. She spoke her first word at age 3.5 years. Her parents reported 
that her language skills plateaued at age 5-7 years at which point she was speaking in 3-4 
word sentences with frequent grammatical errors. Paucity of speech and marked word 
retrieval difficulties were noted at age 9 years, at which time her neurologic exam revealed 
no focal findings beyond the aforementioned developmental delays.
Her first seizure, a prolonged generalized tonic-clonic convulsion, occurred at 8 years of age 
at which time antiepileptic therapy was initiated. Electroencephalogram (EEG) at age 9 
years revealed mild background slowing in full wakefulness, as well as frequent epileptiform 
discharges without clinical correlate, including 3.0-3.5 Hertz (Hz) spike and slow wave 
discharges with bifrontal predominance, frequent runs of semi-rhythmic generalized 3 Hz 
slowing maximal over the left frontal region, and frequent runs of irregular sharp-slow wave 
activity, predominantly occurring over the right posterior quadrant. These discharges 
increased in frequency with sleep, occupying 65-70% of her sleep record. This initially 
responded to high-dose (1 mg/kg) diazepam with significant improvement of her EEG and 
some improvement in her speech and motor skills. Her EEG, however, again worsened with 
increasingly frequent bursts of generalized 3-4 Hz spike and wave activity in wakefulness 
and increasingly frequent generalized spikes in sleep. Her epilepsy both evolved and 
progressed, despite management with multiple antiepileptic medications (including 
valproate, with no resultant liver dysfunction) with focal seizures and epilepsia partialis 
continua occurring with increased frequency starting at 10 years of age. At age 13, she 
developed status epilepticus and progressed to have multiple subsequent events of status 
epilepticus that proved refractory to standard medical management, two experimental 
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medical trials, the ketogenic diet, and corpus callostomy. This progression of her epilepsy 
was accompanied by the development and progressive worsening of non-epileptic 
myoclonus. Notably, the corpus callostomy was complicated by subdural fluid collection 
requiring external ventricular drain placement. MRI brain at that time revealed extensive 
areas of abnormal T2 hyperintensity in the frontal lobes (right greater than left), anterior 
cingulate gyri, left superior frontal gyrus, bilateral temporal lobes, and left cerebellar cortex 
in the setting of recent seizure. MR spectroscopy in the left basal ganglia region 
demonstrated an unremarkable metabolic spectrum. Repeat multi voxel MR spectroscopy of 
the bilateral cerebral hemispheres one year later also showed normal metabolite ratios.
Despite a notable absence of disease process in any other organ or system, her neurologic 
status progressively deteriorated throughout this time. She had a mild decline in skills from 
ages 9-10 after an initial improvement following diazepam administration, and further 
decline with her convulsive seizures beginning at age 10. The patient's neurological status 
precipitously declined after the onset of her initial episode of status epilepticus at age 13 
and, 10 days prior to death at the age of 15 years, her neurologic exam was notable for 
inability follow commands or track faces, bilaterally unreactive pupils, near-continuous 
myoclonus of the right face, arm, and leg, absence of purposeful movement, and up-going 
toes bilaterally. Repeat MRI brain performed 2 months prior to death demonstrated the 
presence of the known fluid collection as well as T2 hyperintensity within the left caudate 
and left medial temporal lobe, and the right medial occipital lobe along the superior bank of 
the right calcarine sulcus with encephalomalacia of the calcaravis (figure 4). EEG performed 
weeks prior to death revealed generalized, irregular theta and delta background slowing and 
near-continuous bi-hemispheric independent and synchronous epileptiform discharges over 
the fronto-temporal regions with shifting side predominance, at times corresponding to 
myoclonus, but more often not synchronous with the clinical myoclonus. She was 
hospitalized with likely pneumonia and urinary tract infections and died after being found 
apneic with pulseless arrest. An autopsy was performed.
Enzymatic, histological, and autopsy findings
Skeletal muscle biopsy was obtained at age 14 years and notable for predominantly type 2 
fiber atrophy with rounded, atrophic fibers scattered throughout with rare regenerative fibers 
but without type grouping on H&E, ATPase PH 4.3, 4.6, and 9.4 stains. There was no 
evidence of inflammation or myonecrosis. NADH staining showed targetoid fibers. 
Gomoritrichome, PAS, and oil red O stains demonstrated normal patterns of staining. 
Combined COX/SDH stain was unremarkable. Electron microscopy revealed fibers with 
focal myofibrillary disarray, many myelin figures, abundant enlarged and swollen 
mitochondria containing glycogen and no inclusions (supplemental figure 1).
Polargraphic analysis of oxidative phosphorylation performed at the Center for Inherited 
Disorders of Energy Metabolism (CIDEM, Case Western Reserve University) demonstrated 
normal activity of Complexes I-IV (frozen specimen). Mitochondrial DNA content of 
skeletal muscle (qPCR analysis, performed at Baylor University) was reported at 61% of 
control (within normal). Normal pyruvate dehydrogenase, pyruvate carboxylase activity was 
noted in skin fibroblasts. “Markedly decreased” butyrobetaine, suggestive of a defect in 
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carnitine biosynthesis was noted in the same specimen but these findings are likely 
attributable to the patient's therapeutic ketogenic diet.
Autopsy gross specimens revealed a normal sized heart, enlarged liver (1960gm, normal 
1500-1800gm), superficial hemorrhagic necrosis of the colon, and a small brain (830g, 
normal 1250-1400 g; 1.4% TBW). Microscopic analysis of brain and spinal cord revealed a 
diffuse, predominantly cortical, as well as subcortical process characterized by laminar 
cortical neuron loss and gliosis, diminished subcortical white matter and descending 
corticospinal tracts. The most severely affected regions included the bilateral frontoribital 
cortices and the bilateral primary visual cortices. In frontorbital cortex there was almost 
complete absence of neurons, excessive gliosis, pale white matter, and fragmenting of the 
cortical layers. The primary visual cortex is notable for a devastated line of Genari, almost 
complete absence of neurons, excessive gliosis, pale white matter, and fragmenting of the 
cortical layers extending through cortical layer 5. Notably, a large autopsy series of 32 
patients with Alpers-Huttenlocher syndrome (a progressive degenerative encephalopathy 
related to polymerase gamma mutations) has previously reported characteristic findings of 
macroscopic cortical thinning, microscopic spongiosis with neuronal loss and astrocytosis 
that is most severe in the occipital lobe17, 18. Similar findings were also reported in an infant 
with FARS2 mutations and progressive myoclonus epilepsy10. Additionally, a small region 
of spongiform change was noted in the right thalamus (figure 5) which was reminiscent of 
the spongiform lesions with relative neuronal sparing that have been reported in the basal 
ganglia of patients with Leigh syndrome bilaterally19, though this finding was notably 
unilateral.
Discussion
Here, we report a case of compound heterozygous FARS2 mutations in association with 
childhood onset refractory epilepsy, progressive myoclonus, cortical necrosis similar that 
seen on autopsy in Alpers-Huttenlocher syndrome as well as a previously reported case of 
FARS2 mutation-associated infantile onset disease, and limited basal ganglia spongiform 
findings similar to those observed in Leigh syndrome. We additionally present 
bioinformatics and biochemical data to support a causal link. The clinical course, 
neuroimaging, and neuropathological findings10 we report are strikingly similar to cases 
described in association with distinct FARS2 mutations in two previous publications10, 11, 
with the exception of age of onset, supporting a genetic association while suggesting an 
attenuated phenotype in this case. Together, these data support a distinct neuropathologic 
process related to perturbations of mtPheRS function. This report underscores the 
phenotypic variability associated with FARS2 mutations and highlights the utility of genetic 
testing in cases of severe, refractory epilepsy and developmental delay.
The data presented here provides a plausible explanation for pathogenicity of the FARS2 
mutations observed. Taken together, the kinetic assays support a deficiency in the activation 
of amino acid for P85A, and a deficiency in the transfer of activated amino acid to tRNA for 
H135D mtPheRS. Additionally, P85A mtPheRS proteins demonstrated decreased stability at 
body temperature.
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Because proline-85 is buried and surrounded by 5 aromatic residues within a 5Å radius 
(histidine-48, tyrosine-288, phenylalanine-296, phenylalanine-303, and phenylalanine-307), 
it is conceivable that perturbation of this residue might impact the stability of tertiary 
structural elements. Regarding the H135D substitution, review of the tRNAPhe bound T. 
thermophilus PheRS structure reveals that the sidechain hydroxyl group of tyronsine-267 
lies within 3.5Å of a histidine-135 nitrogen, creating the possibility of a weak electrostatic 
interaction that might influence the tertiary structure of two loops that surround the acceptor 
stem of the tRNA. Disruption of such an interaction by charge reversal at the 135 position 
could potentially interfere with the binding of the acceptor stem, a possibility supported by 
experiments with recombinant mutant proteins. Presumably, these defects are each less 
potent than those observed in previously published cases.
Two features of interest are raised by this case. This case represents compound heterozygous 
mutations of a mt-aaRS, which has been seen in a preponderance of reports linking mt-aaRS 
mutations and clinical phenotypes, perhaps due to a frequently embryonic lethal 
homozygous phenotype in the case of most mt-aaRS mutations1 Additionally, despite 
variation in severity of clinical presentation and duration of illness (presumably sufficient to 
impact other organ systems), the apparent nervous system-specificity of published 
phenotypes associated with FARS2 perturbations is preserved. Similar tissue or organ 
system specificities have been noted with genetic perturbation of other mitochondrial mt-
aaRS2, 3, 4, 5, 6. It remains to be determined whether this is a result of a relative but 
differential impact on the expression of specific mitochondrially encoded peptides or the 
crossing of a threshold of generalized organelle dysfunction to which a given tissue—
particularly nervous system tissues—might be more sensitive. Further work is required to 
more precisely delineate the pathogenic mechanisms underlying mutations in mt-aaRS 
proteins as well as all diseases affecting mitochondrial translation.
Acknowledgments
Funding: Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology 
and Neuroradiology (R25), (RFAs: NS-09-001, NS-10-002, NS-12-003) to M.A.W.
National Science Foundation MCB- 1412611 to M.I.
References
1. Konovalova S, Tyynismaa H. Mitochondrial aminoacyl-tRNA synthetases in human disease. Mol 
Genet Metabol. 2013; 108:206–211.
2. Hallmann K, Zsurka G, Moskau-Hartmann S, Kirschner J, Korinthenberg R, Ruppert AK, Ozdemir 
O, Weber Y, Becker F, Lerche H, Elger CE, Thiele H, Nürnberg P, Sander T, Kunz WS. A 
homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy. 
Neurology. 2014; 83:2183–7. [PubMed: 25361775] 
3. Scheper GC, van der Klok T, van Andel RJ, van Berkel CG, Sissler M, Smet J, Muravina TI, Serkov 
SV, Uziel G, Bugiani M, Schiffmann R, Krägeloh-Mann I, Smeitink JA, Florentz C, Van Coster R, 
Pronk JC, van der Knaap MS. Mitochondrial aspartyl-tRNA synthetase deficiency causes 
leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet. 
2007; 39:534–9. [PubMed: 17384640] 
4. Steenweg ME, Ghezzi D, Haack T, Abbink TE, Martinelli D, van Berkel CG, Bley A, Diogo L, 
Grillo E, Te Water Naudé J, Strom TM, Bertini E, Prokisch H, van der Knaap MS, Zeviani M. 
Walker et al. Page 9
J Child Neurol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Leukoencephalopathy with thalamus and brainstem involvement and high lactate ‘LTBL’ caused by 
EARS2 mutations. Brain. 2012; 135:1387–94. [PubMed: 22492562] 
5. Bayat V, Thiffault I, Jaiswal M, Tétreault M, Donti T, Sasarman F, Bernard G, Demers-Lamarche J, 
Dicaire MJ, Mathieu J, Vanasse M, Bouchard JP, Rioux MF, Lourenco CM, Li Z, Haueter C, 
Shoubridge EA, Graham BH, Brais B, Bellen HJ. Mutations in the mitochondrial methionyl-tRNA 
synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. 
PLoS Biol. 2012; 10(3):e1001288. [PubMed: 22448145] 
6. Edvardson S, Shaag A, Kolesnikova O, Gomori JM, Tarassov I, Einbinder T, Saada A, Elpeleg O. 
Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with 
pontocerebellar hypoplasia. Am J Hum Genet. 2007; 81:857–62. [PubMed: 17847012] 
7. Rotig A. Human diseases with impaired mitochondrial protein synthesis. Biochim Biophys Acta. 
2011; 1807:1198–1205. [PubMed: 21708121] 
8. Brandon MC, Lott MT, Nguyen KC, Spolim S, Navathe SB, Baldi P, Wallace DC. MITOMAP: a 
human mitochondrial genome database--2004 update. Nucleic Acids Res. 2005 Jan 1; 33(Database 
issue):D611–3. [PubMed: 15608272] 
9. Shamseldin HE, Alshammari M, Al-Sheddi T, Salih MA, Alkhalidi H, Kentab A, Repetto GM, 
Hashem M, Alkuraya FS. Genomic analysis of mitochondrial diseases in a consanguineous 
population reveals novel candidate disease genes. J Med Genet. 2012; 49:234–41. [PubMed: 
22499341] 
10. Elo JM, Yadavalli SS, Euro L, Isohanni P, Götz A, Carroll CJ, Valanne L, Alkuraya FS, Uusimaa J, 
Paetau A, Caruso EM, Pihko H, Ibba M, Tyynismaa H, Suomalainen A. Mitochondrial 
phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. Hum Mol 
Genet. 2012; 21:4521–9. [PubMed: 22833457] 
11. Almalki A, Alston CL, Parker A, Simonic I, Mehta SG, He L, Reza M, Oliveira JM, Lightowlers 
RN, McFarland R, Taylor RW, Chrzanowska-Lightowlers ZM. Mutation of the human 
mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c 
oxidase deficiency. Biochim Biophys Acta. 2014; 1842:56–64. [PubMed: 24161539] 
12. The PyMOL Molecular Graphics System, Version 1.8. Schrödinger, LLC; 
13. Yadavalli SS, Klipcan L, Zozulya A, Banerjee R, Svergun D, Safro M, Ibba M. Large-scale 
movement of functional domains facilitates aminoacylation by human mitochondrial phenylalanyl-
tRNA synthetase. FEBS Lett. 2009; 583:3204–3208. [PubMed: 19737557] 
14. Kyte J, Doolittle R. A simple method for displaying the hydropathic character of a protein. J Mol 
Biol. 1982; 157:105–132. [PubMed: 7108955] 
15. Klipcan L, Levin I, Kessler N, Moor N, Finarov I, Safro M. The tRNA-Induced Conformational 
Activation of Human Mitochondrial Phenylalanyl-tRNASynthetase. Structure. 2008; 16:1095–
1104. [PubMed: 18611382] 
16. Goldgur Y, Mosyak L, Reshetnikova L, Ankilova V, Lavrik O, Khodyreva S, Safro M. The crystal 
structure of phenylalanyl-tRNAsynthetase from thermusthermophilus complexed with cognate 
tRNAPhe. Structure. 1997; 5:59–68. [PubMed: 9016717] 
17. Harding BN. Progressive Neuronal Degeneration of Childhood with Liver Disease (Aplers-
Huttenlocher Syndrome): A Personal Review. J Child Neurol. 1990; 5:273–87. [PubMed: 
2246481] 
18. Naviaux RK, Nguyen KV. POLG mutations associated with Alpers' syndrome and mitochondrial 
DNA depletion. Ann Neurol. 2004; 55:706–12. [PubMed: 15122711] 
19. M Gerards, M.; Sallevelt, SCEH.; Smeets, HJM. Leigh syndrome: Resolving the clinical and 
genetic heterogeneity paves the way for treatment options. Mol Genet Metab. 2015. http://
dx.doi.org/10.1016/j.ymgme.2015.12.004
Walker et al. Page 10
J Child Neurol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 1. Multiple sequence alignment of orthologous proteins
Multiple sequence alignment of N-terminal mitochondrial phenylalanyl transfer RNA 
synthetase peptide sequences from multiple species. Conserved residues are presented in 
green. The location of the mutations carried by the patient are boxed in red (proline-85) and 
blue (histidine-135). Both residues are highly conserved through bacterial species.
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Figure 2. Structure-guided analysis of FARS2 mutations
Structure-guided analysis of FARS2 mutations. Phe-AMP bound FARS2 quarternary 
structure with domains labeled (PBD id 3CMQ), the locations of proline-85 and 
histidine-135 are highlighted in red and blue, respectively (A). proline-85 is buried within 
several aromatic residues (B). histidine-135 is located within conserved inter-motif region 
forming one of two catalytic domain loops which associate with the acceptor stem of the 
tRNA molecule in the crystal structure of the orthologous protein T. Thermophilus-PheRS-
bound to tRNA-Phe (PBD id 1EIY), pictured here in cyan with orthologous domain aligned 
with FARS2 in green, tRNA-Phe is drawn in yellow.
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Figure 3. Analysis of recombinant mutant enzymes
Recombinant mutant mtPheRS proteins were expressed and purified in E. coli per 
established protocols. End point aminoacylation reactions indicated that mutant P85A 
mtPheRS charges tRNA very similarly to WT, but H135D demonstrated severe 
aminoacylation deficiency. Determination of the steady-state kinetics for tRNA revealed that 
mutant P85A has a two-fold increase in catalytic efficiency when compared to WT, while 
kinetic parameters for H135D were unable to be determined using standard techniques, 
reinforcing the previously observed aminoacylation deficiency. End-point pyrophosphate 
exchange experiments were also performed. At a phenylalanine concentration of 15 μM, 
twice the reported Km for human mtPheRS, mutant P85A is unable to produce a measurable 
amount of activity, suggesting that the Km of P85A for phenylalanine is higher than the 
reported WT value. Mutant H135D mtPheRS showed a moderate amount of activity, 
suggesting that the observed aminoacylation deficiency is likely due to a defect in tRNA 
binding and not amino acid activation. The stability of WT and mutant proteins was assessed 
by active site titration after incubation at either room temperature or 37 °C. At room 
temperature, neither mutation has a measurable impact on protein stability. However, when 
tested at 37 °C, mutant P85A appears to have decreased stability when compared to WT.
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Figure 4. MRI brain
MRI brain performed at age 15 years, 2 months prior to death revealing T2 hyperintensity 
within the left caudate and left medial temporal lobe, and the right medial occipital lobe 
along the superior bank of the right calcarine sulcus with encephalomalacia of the calcaravis. 
Notably, earlier corpus callostomy for refractory seizures was complicated by the right 
subdural fluid collection also seen in this image, requiring external ventricular drain 
placement.
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Figure 5. Microscopic analysis of brain and spinal cord on autopsy
Microscopic analysis of the brain and spinal cord revealed a diffuse, predominantly cortical, 
as well as subcortical process characterized by laminar cortical neuron loss and gliosis, with 
the the primary visualcortex, seen in low (A) and high (B) power, and the lateral occipital 
cortex, seen in low (C) and high (D) power markedly affected. A single focal region of 
spongiform change was observed in the thalamus, shown at low (E) and high (F) power.
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Table 2
Summary of Pathologic Findings
Summary of autopsy brain histology features found in the case presented, a previously published case of 
infantile onset FARS2 mutation associated disease, Alpers-Huttenlocher Syndrome, and Leigh Syndrome
Case presented Infantile onset FARS2 case 
(Elo et al., 2012)
Alpers-Huttenlocher 
Syndrome (Harding, 
1990)
Leigh Syndrome 
(Gerards et al., 2015)
Microscopic Findings Finding 1. Almost 
complete absence of 
neurons, excessive 
gliosis, pale white 
matter, and 
fragmenting of the 
cortical layers.
Finding 2. Spongiform 
change
Finding 1. “Striking and 
subtotal laminar necrosis of the 
whole cortical ribbon. 
Degeneration … was almost 
total, with … mid-laminar 
microcystic degeneration with 
reactive gliosis and capillary 
proliferation…”
Finding 2. “Neuronal 
degeneration with atrophy and 
gliosis ….”
Finding 3. “Severely atrophic 
with Purkinje cell drop-out, 
narrowed molecular and 
granular layers”
“Laminar dehiscence … 
mild superficial 
astrocytosis through 
increasing sponginess, 
nerve cell loss, and 
gliosis, until the whole 
ribbon is thinned and 
depleted of nerve cells 
and the neuropil is 
disorganized and 
replaced by hypertrophic 
fiber-forming astrocytes 
and a prominent 
vascularity.”
“Microscopically, they 
have a spongiform 
appearance due to 
hypervascularity with 
capillary proliferation and 
endothelial swelling, and 
they are associated with 
gliosis and demyelination, 
with relative sparing of 
neurons.”
Region of greatest 
severity
Finding 1. Occipital 
cortex, frontal cortex
Finding 2. Right 
thalamus
Finding 1. Frontal cortex
Finding 2. Basal ganglia
Finding 3. Cerebellar cortex
Calcarine cortex Basal ganglia, thalamus, 
brain stem, cerebellum, 
optic nerves, & spinal 
cord
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